CYP2D6 polymorphisms and atypical antipsychotic weight gain

Area of Science:

• Pharmacogenetics
• Metabolism
• Psychiatry

Background:

• Atypical antipsychotics (AAPs) are frequently associated with significant weight gain.
• The cytochrome P450 2D6 (CYP2D6) enzyme, crucial for drug metabolism, exhibits genetic polymorphism.
• CYP2D6 genetic variations have been linked to adverse drug reactions and treatment outcomes.

Purpose of the Study:

• To investigate the association between CYP2D6 genetic polymorphisms and olanzapine-induced weight gain.
• To determine if specific CYP2D6 genotypes correlate with the extent of body mass index (BMI) changes in patients treated with olanzapine.

Main Methods:

• Genotyping of CYP2D6 in eleven subjects receiving olanzapine.
• Linear regression analysis was employed to assess the relationship between variables.
• Percent change in BMI was the dependent variable, with genotype, dose, and duration as independent variables.

Main Results:

• A significant association (P<0.0097) was found between CYP2D6 genotype and weight gain.
• Subjects with *1/*3 or *4 CYP2D6 genotypes experienced a greater percent change in BMI compared to those with the *1/*1 genotype.
• This suggests that certain CYP2D6 variants may lead to increased olanzapine exposure and subsequent weight gain.

Conclusions:

• CYP2D6 genotype is a significant predictor of olanzapine-induced weight gain.
• Pharmacogenetic profiling of CYP2D6 may aid in predicting and managing AAP-related weight gain.
• Further research is warranted to elucidate the precise mechanisms linking CYP2D6 genotype to AAP-induced metabolic changes.